NextCure
NXTC
44 hedge funds and large institutions have $161M invested in NextCure in 2019 Q2 according to their latest regulatory filings, with 44 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
3.95% more ownership
Funds ownership: 0% → 3.95% (+4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$47M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$43.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$18.9M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$17.3M |
| 5 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$17M |
Top Sellers
NXTC Hedge Fund Activity: Q2 2019 in Review
44 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q2 2019, worth a combined $161M.
Buyers outnumbered sellers: 44 funds opened new NXTC positions and 0 closed out — a net gain of 44 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $47M.
- 44 institutional investors held NextCure (NXTC) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $161M of NextCure stock for Q2 2019.
- 44 funds opened new NextCure positions in Q2 2019 and 0 closed out, a net change of +44 holders.
- The largest NextCure buyer in Q2 2019 was OrbiMed, an estimated $47M added.
Based on aggregated 13F filings for Q2 2019.